Medscape covers a study of mostly African American and Hispanic patients with severe obesity where surgery led to over twice the weight loss.
Recap by typeshit. Full story at Medscape.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
BiopharmIQ also notes TRIUMPH-5, which pits retatrutide directly against tirzepatide, is still running. That sets the timeline for a possible approval filing.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Loading…